sur Theranexus (EPA:ALTHX)
Theranexus Announces Its Cash Position as of September 30, 2024
Theranexus, a company specializing in the treatment of rare neurological diseases, has published its cash position at the end of the third quarter of 2024. The company's cash position stands at €1.9 million, compared to €1.8 million as of June 30, 2024. This increase includes the 2024 Research Tax Credit of €785,000.
CEO Mathieu Charvériat highlights the company's commitment to the European registration of their new treatment for Niemann-Pick C disease, and the launch of phase 3 for Batten disease. Theranexus continues to explore opportunities with industrial partners to develop its products in lucrative markets.
The cash horizon is maintained until the end of the first quarter of 2025.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus